论文部分内容阅读
目的比较替尼泊甙（ＶＭ－１６）与依托泊甙（ＶＰ－１６）对晚期非小细胞肺癌的疗效。方法晚期非小细胞肺癌６１例，随机分为Ａ、Ｂ两组，Ａ组应用顺铂（ＤＤＰ）＋ＶＰ－１６方案化疗，Ｂ组应用ＤＤＰ＋ＶＭ－２６方案化疗，２～３周期化疗后评价疗效和不良作用。结果Ａ组有效率为３７．５％（１２／３２），Ｂ组有效率为３３．３％（７／２１），两组无显著差异。Ａ组与Ｂ组Ⅲ～Ⅳ级骨髓毒性发生率分别为２８．１％和２３．８％，Ⅱ～Ⅲ级胃肠道毒性发生率分别为３１．３％和２３．８％。结论ＶＭ－２６治疗晚期非小细胞肺癌的有效率与ＶＰ－１６相似，而不良反应发生率低。
Objective To compare the efficacy of teniposide (VM-16) and etoposide (VP-16) in advanced non-small cell lung cancer. Methods Sixty-one patients with advanced non-small cell lung cancer were randomly divided into A and B groups. Group A was treated with cisplatin (DDP)+VP-16 chemotherapy, group B was treated with DDP+VM-26 chemotherapy, and efficacy was evaluated after 2 to 3 cycles of chemotherapy. Bad effect. Results The effective rate was 37.5% (12/32) in group A and 33.3% (7/21) in group B. There was no significant difference between the two groups. The incidence of grade III-IV bone marrow toxicity in group A and group B was 28.1% and 23.8%, and the incidence of grade II-III gastrointestinal toxicity was 31.3% and 23.8%, respectively. Conclusion VM-26 is more effective than VP-16 in the treatment of advanced non-small cell lung cancer, but the incidence of adverse reactions is low.